Strategic Partnerships Potential to expand collaboration with pharma and biotech players through VisAcT and novel PET probes, leveraging existing partnerships with Boehringer Ingelheim and Telix to accelerate co-development and licensing opportunities.

Immuno-Oncology Focus Strong alignment with immuno-oncology therapies through imaging companions that visualize activated T cells and therapeutic cell migration, offering a compelling value proposition to companies developing IO treatments seeking rapid efficacy readouts.

Clinical Readout Advantage Recent eIND approvals suggest capability to provide early, actionable efficacy data in days rather than months, enabling faster decision-making for clinical programs and potential acceleration of development timelines.

Strategic Access Small company with high-value, high-ROI imaging tools presents low-to-mid risk entry for larger CROs and biopharma to embed advanced PET imaging capabilities into their clinical development pipelines.

Tech & Services Readiness Robust tech stack and established imaging platforms, plus a focused pipeline of PET tracers, create opportunities to partner on manufacturing support, regulatory strategy, and scalable deployment across multiple clinical sites.